§ Same category · GLP-1 / metabolic peptides
Orforglipron vs Retatrutide
Side-by-side price comparison across every tracked vendor. Updated every 4–6 hours.
Pepticker may earn affiliate commissions (typically 5-20%) from linked vendors. See our Affiliate Disclosure.
Orforglipron
0
vendors tracked
Retatrutide
0
vendors tracked
Orforglipron
Oral small-molecule GLP-1 agonist
No current listings at 0.024mg.
Retatrutide
Triple GCG/GIP/GLP-1 agonist
No current listings at 10mg.
About Orforglipron
An oral non-peptide GLP-1 receptor agonist in Phase 3 for obesity and type-2 diabetes. Typically sold as capsules in research-compound form.
About Retatrutide
An investigational triple-agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 clinical trials for obesity are ongoing; research-compound version is sold via research-chemical vendors.